CTLA4 and neoplasm: This nanoformulation in combination with anti-CTLA4 was tested in vivo in B16F10 tumor mice model, where the reduction in tumor volume was observed comparing to anti-CTLA4 combinations with untargeted nanocomplexes or with naked ODN1826 (216).